Deborah K. Armstrong

1988–2025 年に発表

94
論文数
30,463
被引用数
70
h 指数
91
i10 指数

被引用数

Deborah K. Armstrong の年別被引用数1990 年: 被引用 3 件1991 年: 被引用 9 件1992 年: 被引用 14 件1993 年: 被引用 24 件1994 年: 被引用 24 件1995 年: 被引用 26 件1996 年: 被引用 22 件1997 年: 被引用 29 件1998 年: 被引用 23 件1999 年: 被引用 25 件2000 年: 被引用 27 件2001 年: 被引用 27 件2002 年: 被引用 36 件2003 年: 被引用 31 件2004 年: 被引用 33 件2005 年: 被引用 36 件2006 年: 被引用 68 件2007 年: 被引用 101 件2008 年: 被引用 111 件2009 年: 被引用 130 件2010 年: 被引用 129 件2011 年: 被引用 123 件2012 年: 被引用 127 件2013 年: 被引用 105 件2014 年: 被引用 141 件2015 年: 被引用 121 件2016 年: 被引用 138 件2017 年: 被引用 169 件2018 年: 被引用 352 件2019 年: 被引用 1,275 件2020 年: 被引用 1,464 件2021 年: 被引用 1,383 件2022 年: 被引用 1,086 件2023 年: 被引用 782 件2024 年: 被引用 1,070 件2025 年: 被引用 504 件2026 年: 被引用 11 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,533 件、この内訳の 27.8%中国: 引用元論文 1,605 件、この内訳の 12.6%イタリア: 引用元論文 773 件、この内訳の 6.1%イギリス: 引用元論文 771 件、この内訳の 6.1%ドイツ: 引用元論文 529 件、この内訳の 4.2%フランス: 引用元論文 521 件、この内訳の 4.1%日本: 引用元論文 501 件、この内訳の 3.9%カナダ: 引用元論文 440 件、この内訳の 3.5%スペイン: 引用元論文 424 件、この内訳の 3.3%オランダ: 引用元論文 309 件、この内訳の 2.4%オーストラリア: 引用元論文 300 件、この内訳の 2.4%韓国: 引用元論文 292 件、この内訳の 2.3%
0%27.8%その他 21.3%

分野

  • Medicine74.8%
  • Biochemistry, Genetics and Molecular Biology17.9%
  • Immunology and Microbiology3.8%
  • Materials Science0.9%
  • Engineering0.8%
  • Computer Science0.4%
  • その他1.4%

トピック

  • Ovarian cancer diagnosis and treatment9.3%
  • Cancer Immunotherapy and Biomarkers7.8%
  • PARP inhibition in cancer therapy6.1%
  • Cancer Genomics and Diagnostics3.4%
  • Genetic factors in colorectal cancer3%
  • Intraperitoneal and Appendiceal Malignancies2.8%
  • その他67.6%

共著者

全論文

検索で開く
  1. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shibin Zhou, Richard M. Goldberg, Deborah K. Armstrong, Katherine M. Bever, Amanda N. Fader, Janis M. Taube, Franck Housseau, David Spetzler, Nianqing Xiao, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, James R. Eshleman, Bert Vogelstein, Robert A. Anders, Luis A. Díaz - Science 2017 被引用: 6,766

  2. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson ほか 21 名 - The Lancet Oncology 2017 被引用: 1,863

  3. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian ほか 17 名 - The Lancet 2017 被引用: 1,704

  4. NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsíros, Mary A. Dwyer, Lisa E. Hang - Journal of the National Comprehensive Cancer Network 2022 被引用: 398

  5. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Theresa L. Werner, Emese Zsíros, Jennifer L. Burns, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2021 被引用: 713

  6. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano ほか 23 名 - The Lancet Oncology 2021 被引用: 416

  7. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 296

  8. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 被引用: 602

  9. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

    著者: , , , , , , , , - New England Journal of Medicine 2006 被引用: 2,625

  10. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis

    著者: , , , , - Journal of Clinical Oncology 2002 被引用: 2,327

  11. C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2023 被引用: 77

  12. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline

    著者: , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 379

  13. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 127

  14. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 334

  15. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

    著者: , , , , , , , , , , , , , , , , , , , , , - Gynecologic Oncology 2021 被引用: 117

  16. Recent progress in the diagnosis and treatment of ovarian cancer

    著者: , - CA A Cancer Journal for Clinicians 2011 被引用: 772

  17. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse

    著者: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 159

  18. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 被引用: 90

  19. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jennifer L. Burns, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2019 被引用: 332

  20. NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael McHale, Sanja Percac‐Lima, Kerry J. Rodabaugh, Roberto Vargas, Frankie Jones, E Kovách, Lisa E. Hang, Swathi Ramakrishnan, Ronald D. Alvarez, Deborah K. Armstrong - Journal of the National Comprehensive Cancer Network 2024 被引用: 110

  21. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

    著者: , , , , , , , , , , , , , , , , - Gynecologic Oncology 2016 被引用: 411

  22. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lori M. Minasian, Nora Horick, Carol H. Kasten, Susan Nayfield, David S. Alberts, Dianne M. Finkelstein, Karen H. Lu - Clinical Cancer Research 2017 被引用: 139

  23. Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    著者: , , , , , , , , , - Journal of Clinical Oncology 2007 被引用: 846

  24. Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

    著者: , , , , , , , , , , - Journal of Clinical Oncology 2007 被引用: 756